SSM Score for Liver Injury in Chronic Liver Disease
Part of Digestive system clinical trials.
This study looks at how well a simple score (called SSM) can predict recovery in people with chronic liver disease who suddenly get a liver injury with jaundice. It may help your doctors understand how serious your condition is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a chronic (long-term) liver condition of any cause (for example, cirrhosis or hepatitis).
- You have a sudden worsening of your liver, with jaundice and a bilirubin level of 3 mg/dL or higher.
- You have not had a liver transplant, TIPS procedure, or spleen surgery for your liver disease.
- You do not have severe lung disease, kidney failure on dialysis, or a recent heart attack.
- You are not being treated with immune-suppressing drugs for a reason other than your liver disease.
- You do not have liver cancer or any other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether measuring spleen stiffness and simple blood tests can predict if the liver will recover in people with decompensated cirrhosis. It may help doctors know which patients can improve with treatment.
This study uses a simple ultrasound-based test (FibroScan) to check liver stiffness and predict whether you have high pressure in the veins around the liver. It aims to see if a new set of criteria can safely tell who needs an endoscopy, helping avoid unnecessary procedures.
This study tests a more detailed way to examine the liver in people with fatty liver disease who also have other health risks. The doctors want to see if this extra testing helps decide whether you need treatment.
This study looks at new, non-invasive methods to predict when chronic liver disease might get worse. It could help you and your doctor catch problems early without needing a biopsy or other invasive procedures.
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Hear when a new End Stage Liver DIsease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.